, Tracking Stock Market Picks
Enter Symbol:
Vanda Pharmaceuticals Inc. (VNDA) [hlAlert]

down 8.05 %

Vanda Pharmaceuticals Inc. (VNDA) rated Buy with price target $22 by Canaccord Genuity

Posted on: Friday,  Jan 9, 2015  10:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on 01/09/2015, when the stock price was $13.04. Since
then, Vanda Pharmaceuticals Inc. has lost 8.05% as of 01/27/2016's recent price of $11.99.
If you would have followed this Canaccord Genuity's recommendation on VNDA, you would have lost 8.05% of your investment in 383 days.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/9/2015 10:25 AM Buy
13.04 22.00
as of 8/27/2015
1 Week up  1.01 %
1 Month down  -7.05 %
3 Months up  20.86 %
1 YTD down  -8.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy